Funding
Scholarships to Dr. Lisiane C Poncio, Ms. Thatyanne GF do Nascimento and
Mr. Nilton de F Junior were provided by Coordenação de Aperfeiçoamento
de Pessoal de Nível Superior (CAPES, Brazil; Finance code 001), and the
scholarship to Dr Aline S Fonseca was provided by the Conselho Nacional
de Desenvolvimento Científico e Tecnológico (CNPq, Brazil).
Additionally, the Genomics and Epigenomics Shared Resource (GESR)
partially supported the present study (grant no. P30-CA051008).
Data Availability Statement: The data that support the findings
of this study are available from the corresponding author upon
reasonable request.
REFERENCES
1. Tolbert VP, Matthay KK. Neuroblastoma: clinical and biological
approach to risk stratification and treatment. Cell Tissue Res .
05 2018;372(2):195-209. doi:10.1007/s00441-018-2821-2
2. Matthay KK, Maris JM, Schleiermacher G, et al. Neuroblastoma.Nat Rev Dis Primers . 11 2016;2:16078. doi:10.1038/nrdp.2016.78
3. Maguire LH, Thomas AR, Goldstein AM. Tumors of the neural crest:
Common themes in development and cancer. Dev Dyn . Mar
2015;244(3):311-22. doi:10.1002/dvdy.24226
4. Morgenstern DA, London WB, Stephens D, et al. Prognostic significance
of pattern and burden of metastatic disease in patients with stage 4
neuroblastoma: A study from the International Neuroblastoma Risk Group
database. Eur J Cancer . 09 2016;65:1-10.
doi:10.1016/j.ejca.2016.06.005
5. Moreno L, Rubie H, Varo A, et al. Outcome of children with relapsed
or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European
phase II clinical trials. Pediatr Blood Cancer . 01
2017;64(1):25-31. doi:10.1002/pbc.26192
6. Zhou MJ, Doral MY, DuBois SG, Villablanca JG, Yanik GA, Matthay KK.
Different outcomes for relapsed versus refractory neuroblastoma after
therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG). Eur J
Cancer . Nov 2015;51(16):2465-72. doi:10.1016/j.ejca.2015.07.023
7. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the
international criteria for neuroblastoma diagnosis, staging, and
response to treatment. J Clin Oncol . Aug 1993;11(8):1466-77.
doi:10.1200/JCO.1993.11.8.1466
8. Meany HJ. Non-High-Risk Neuroblastoma: Classification and
Achievements in Therapy. Children (Basel) . Jan 2019;6(1)doi:
https://doi.org/10.3390/children6010005
9. Aygun N. Biological and Genetic Features of Neuroblastoma and Their
Clinical Importance. Curr Pediatr Rev . Jan 28 2018;14(2):73-90.
doi:10.2174/1573396314666180129101627
10. Mlakar V, Jurkovic Mlakar S, Lopez G, Maris JM, Ansari M, Gumy-Pause
F. 11q deletion in neuroblastoma: a review of biological and clinical
implications. Mol Cancer . 06 2017;16(1):114.
doi:10.1186/s12943-017-0686-8
11. Larsson K, Kock A, Idborg H, et al. COX/mPGES-1/PGE2 pathway depicts
an inflammatory-dependent high-risk neuroblastoma subset. Proc
Natl Acad Sci U S A . Jun 2015;112(26):8070-5.
doi:10.1073/pnas.1424355112
12. Korbecki J, Baranowska-Bosiacka I, Gutowska I, Chlubek D.
Cyclooxygenase pathways. Acta Biochim Pol . 2014;61(4):639-49.
13. Dixon DA, Blanco FF, Bruno A, Patrignani P. Mechanistic aspects of
COX-2 expression in colorectal neoplasia. Recent Results Cancer
Res . 2013;191:7-37. doi:10.1007/978-3-642-30331-9_2
14. Cebola I, Peinado MA. Epigenetic deregulation of the COX pathway in
cancer. Prog Lipid Res . Oct 2012;51(4):301-13.
doi:10.1016/j.plipres.2012.02.005
15. Pannunzio A, Coluccia M. Cyclooxygenase-1 (COX-1) and COX-1
Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry
Literature. Pharmaceuticals (Basel) . Oct 11 2018;11(4):20.
doi:10.3390/ph11040101
16. Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K.
Cyclooxygenase-2 in cancer: A review. J Cell Physiol . May
2019;234(5):5683-5699. doi:10.1002/jcp.27411
17. Tong D, Liu Q, Wang LA, et al. The roles of the COX2/PGE2/EP axis in
therapeutic resistance. Cancer Metastasis Rev . 09
2018;37(2-3):355-368. doi:10.1007/s10555-018-9752-y
18. Jansen SR, Holman R, Hedemann I, et al. Prostaglandin E2 promotes
MYCN non-amplified neuroblastoma cell survival via β-catenin
stabilization. J Cell Mol Med . Jan 2015;19(1):210-26.
doi:10.1111/jcmm.12418
19. Menche J, Sharma A, Kitsak M, et al. Disease networks. Uncovering
disease-disease relationships through the incomplete interactome.Science . Feb 2015;347(6224):1257601. doi:10.1126/science.1257601
20. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B.
Terminology and morphologic criteria of neuroblastic tumors:
recommendations by the International Neuroblastoma Pathology Committee.Cancer . Jul 15 1999;86(2):349-63.
21. do Carmo Debur M, Raboni SM, Flizikowski FB, et al.
Immunohistochemical assessment of respiratory viruses in necropsy
samples from lethal non-pandemic seasonal respiratory infections.J Clin Pathol . Oct 2010;63(10):930-4. doi:10.1136/jcp.2010.077867
22. Vaz de Paula CB, de Azevedo MLV, Nagashima S, et al. IL-4/IL-13
remodeling pathway of COVID-19 lung injury. Scientific reports .
Oct 29 2020;10(1):18689. doi:10.1038/s41598-020-75659-5
23. Santos SC, Cavalli IJ, Ribeiro EM, et al. Patterns of DNA copy
number changes in sentinel lymph node breast cancer metastases.Cytogenet Genome Res . 2008;122(1):16-21. doi:10.1159/000151311
24. Torresan C, Oliveira MM, Pereira SR, et al. Increased copy number of
the DLX4 homeobox gene in breast axillary lymph node metastasis.Cancer Genet . May 2014;207(5):177-87.
doi:10.1016/j.cancergen.2014.04.007
25. Sugita B, Gill M, Mahajan A, et al. Differentially expressed miRNAs
in triple negative breast cancer between African-American and
non-Hispanic white women. Oncotarget . Nov 2016;7(48):79274-79291.
doi:10.18632/oncotarget.13024
26. Haeussler M, Zweig AS, Tyner C, et al. The UCSC Genome Browser
database: 2019 update. Nucleic Acids Res . Jan 8
2019;47(D1):D853-D858. doi:10.1093/nar/gky1095
27. Vlachos IS, Kostoulas N, Vergoulis T, et al. DIANA miRPath v.2.0:
investigating the combinatorial effect of microRNAs in pathways.Nucleic Acids Res . Jul 2012;40(Web Server issue):W498-504.
doi:10.1093/nar/gks494
28. Vlachos IS, Paraskevopoulou MD, Karagkouni D, et al. DIANA-TarBase
v7.0: indexing more than half a million experimentally supported
miRNA:mRNA interactions. Nucleic Acids Res . Jan 2015;43(Database
issue):D153-9. doi:10.1093/nar/gku1215
29. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein
association networks with increased coverage, supporting functional
discovery in genome-wide experimental datasets. Nucleic Acids
Res . Jan 8 2019;47(D1):D607-D613. doi:10.1093/nar/gky1131
30. Qu X, Tang Y, Hua S. Immunological Approaches Towards Cancer and
Inflammation: A Cross Talk. Front Immunol . 2018;9:563.
doi:10.3389/fimmu.2018.00563
31. Scardoni G, Petterlini M, Laudanna C. Analyzing biological network
parameters with CentiScaPe. Bioinformatics . Nov
2009;25(21):2857-9. doi:10.1093/bioinformatics/btp517
32. Feltes BC, Poloni JF, Nunes IJG, Faria SS, Dorn M. Multi-Approach
Bioinformatics Analysis of Curated Omics Data Provides a Gene Expression
Panorama for Multiple Cancer Types. Front Genet . 2020;11:586602.
doi:10.3389/fgene.2020.586602
33. Bader GD, Hogue CW. An automated method for finding molecular
complexes in large protein interaction networks. BMC
Bioinformatics . Jan 2003;4:2. doi:10.1186/1471-2105-4-2
34. Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess
overrepresentation of gene ontology categories in biological networks.Bioinformatics . Aug 2005;21(16):3448-9.
doi:10.1093/bioinformatics/bti551
35. Costa RA, Seuánez HN. Investigation of major genetic alterations in
neuroblastoma. Mol Biol Rep . Jun 2018;45(3):287-295.
doi:10.1007/s11033-018-4161-4
36. Carlson LM, Kogner P. Neuroblastoma-related inflammation: May small
doses of aspirin be suitable for small cancer patients?Oncoimmunology . Jul 2013;2(7):e24658. doi:10.4161/onci.24658
37. Comunanza V. Targeting mPGES-1 as a New Strategy against
Neuroblastoma. EBioMedicine . 07 2018;33:14-15.
doi:10.1016/j.ebiom.2018.06.008
38. Johnsen JI, Lindskog M, Ponthan F, et al. Cyclooxygenase-2 is
expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs
induce apoptosis and inhibit tumor growth in vivo. Cancer Res .
Oct 2004;64(20):7210-5. doi:10.1158/0008-5472.CAN-04-1795
39. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation.Cell . Mar 2011;144(5):646-74. doi:10.1016/j.cell.2011.02.013
40. Attar N, Kurdistani SK. Exploitation of EP300 and CREBBP Lysine
Acetyltransferases by Cancer. Cold Spring Harb Perspect Med . Mar
1 2017;7(3):15. doi:10.1101/cshperspect.a026534
41. Yazawa T, Imamichi Y, Yuhki KI, et al. Cyclooxygenase-2 is acutely
induced by CCAAT/enhancer-binding protein beta to produce prostaglandin
E 2 and F 2alpha following gonadotropin stimulation in Leydig cells.Mol Reprod Dev . Jul 2019;86(7):786-797. doi:10.1002/mrd.23163
42. Wang Y, He G, Tang H, et al. Aspirin inhibits inflammation and scar
formation in the injury tendon healing through regulating JNK/STAT-3
signalling pathway. Cell Prolif . Jul 2019;52(4):e12650.
doi:10.1111/cpr.12650
43. Chung ST, Geerts D, Roseman K, Renaud A, Connelly L. Osteoprotegerin
mediates tumor-promoting effects of Interleukin-1beta in breast cancer
cells. Mol Cancer . Feb 1 2017;16(1):27.
doi:10.1186/s12943-017-0606-y
44. Kalmar A, Wichmann B, Galamb O, et al. Gene-expression analysis of a
colorectal cancer-specific discriminatory transcript set on
formalin-fixed, paraffin-embedded (FFPE) tissue samples.Diagnostic pathology . Jul 25 2015;10:126.
doi:10.1186/s13000-015-0363-4
45. Garner EF, Beierle EA. Cancer Stem Cells and Their Interaction with
the Tumor Microenvironment in Neuroblastoma. Cancers (Basel) . Dec
2015;8(1)doi:10.3390/cancers8010005
46. Carter BZ, Mak PY, Wang X, et al. An ARC-Regulated
IL1beta/Cox-2/PGE2/beta-Catenin/ARC Circuit Controls
Leukemia-Microenvironment Interactions and Confers Drug Resistance in
AML. Cancer Res . Mar 15 2019;79(6):1165-1177.
doi:10.1158/0008-5472.CAN-18-0921
47. Fang M, Yuan J, Peng C, Li Y. Collagen as a double-edged sword in
tumor progression. Tumour biology : the journal of the
International Society for Oncodevelopmental Biology and Medicine . Apr
2014;35(4):2871-82. doi:10.1007/s13277-013-1511-7
48. Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages
as major players in the tumor microenvironment. Cancers (Basel) .
Aug 13 2014;6(3):1670-90. doi:10.3390/cancers6031670
49. Buckley PG, Alcock L, Bryan K, et al. Chromosomal and microRNA
expression patterns reveal biologically distinct subgroups of 11q-
neuroblastoma. Clin Cancer Res . Jun 2010;16(11):2971-8.
doi:10.1158/1078-0432.CCR-09-3215